These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 7687708

  • 1. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.
    Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM.
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):856-62. PubMed ID: 7687708
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW.
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [Abstract] [Full Text] [Related]

  • 3. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J, Faülhaber HD.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():77-82. PubMed ID: 15700490
    [Abstract] [Full Text] [Related]

  • 4. [Nebivolol, a beta blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study].
    von Fallois J, Faulhaber HD.
    Praxis (Bern 1994); 2001 Mar 15; 90(11):435-41. PubMed ID: 11293936
    [Abstract] [Full Text] [Related]

  • 5. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
    Cleophas TJ, Agrawal R, Lichtenthal A, Mäkel W, Fici F.
    Am J Ther; 2006 Mar 15; 13(3):192-7. PubMed ID: 16772759
    [Abstract] [Full Text] [Related]

  • 6. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 15; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
    Weiss RJ, Saunders E, Greathouse M.
    Clin Ther; 2011 Sep 15; 33(9):1150-61. PubMed ID: 21864908
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
    Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G.
    Blood Press Suppl; 2003 Dec 15; 2():35-40. PubMed ID: 14761075
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
    Papademetriou V.
    Am J Cardiol; 2009 Jan 15; 103(2):273-8. PubMed ID: 19121451
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM, Keam SJ.
    Am J Cardiovasc Drugs; 2009 Jan 15; 9(4):253-60. PubMed ID: 19655820
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol.
    Yilmaz MB, Erdem A, Yalta K, Turgut OO, Yilmaz A, Tandogan I.
    Adv Ther; 2008 Sep 15; 25(9):871-83. PubMed ID: 18758699
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
    Heitmann J, Greulich T, Reinke C, Koehler U, Vogelmeier C, Becker HF, Schmidt AC, Canisius S.
    Curr Med Res Opin; 2010 Aug 15; 26(8):1925-32. PubMed ID: 20560730
    [Abstract] [Full Text] [Related]

  • 17. EVOLVE (nebivolol evaluation for efficacy and safety in the treatment of hypertension) postmarketing surveillance study.
    Faruqui AA.
    J Indian Med Assoc; 2007 May 15; 105(5):272, 274, 276-7. PubMed ID: 17915798
    [Abstract] [Full Text] [Related]

  • 18. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA.
    Am J Hypertens; 2005 Dec 15; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [Abstract] [Full Text] [Related]

  • 19. Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. the QoLaN study.
    Hermans MP, De Coster O, Seidel L, Albert A, Van de Borne P.
    Blood Press Suppl; 2009 Oct 15; 1():5-14. PubMed ID: 20050100
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.
    Rosei EA, Rizzoni D, Comini S, Boari G, Nebivolol-Lisinopril Study Group.
    Blood Press Suppl; 2003 May 15; 1():30-5. PubMed ID: 12800985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.